Log in

NASDAQ:JAZZJazz Pharmaceuticals Competitors & Alternatives

$111.20
+1.45 (+1.32 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$109.86
Now: $111.20
$112.16
50-Day Range
$104.68
MA: $112.45
$121.88
52-Week Range
$86.88
Now: $111.20
$154.24
Volume429,732 shs
Average Volume677,737 shs
Market Capitalization$6.15 billion
P/E Ratio23.12
Dividend YieldN/A
Beta1.23

Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs. JNJ, MRK, PFE, LLY, ABBV, and BMY

Should you be buying JAZZ stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Jazz Pharmaceuticals, including Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Insider & Institutional Ownership

68.5% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Johnson & Johnson and Jazz Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion4.59$15.12 billion$8.6816.47
Jazz Pharmaceuticals$2.16 billion2.85$523.37 million$14.607.62

Johnson & Johnson has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Johnson & Johnson has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Johnson & Johnson and Jazz Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson041202.75
Jazz Pharmaceuticals051302.72

Johnson & Johnson presently has a consensus price target of $163.8571, suggesting a potential upside of 14.60%. Jazz Pharmaceuticals has a consensus price target of $157.1765, suggesting a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Johnson & Johnson.

Profitability

This table compares Johnson & Johnson and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson24.47%39.71%15.27%
Jazz Pharmaceuticals12.81%21.66%11.90%

Merck & Co., Inc. (NYSE:MRK) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Volatility & Risk

Merck & Co., Inc. has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Insider and Institutional Ownership

74.3% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Merck & Co., Inc. and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.29$9.84 billion$5.1915.33
Jazz Pharmaceuticals$2.16 billion2.85$523.37 million$14.607.62

Merck & Co., Inc. has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.21.10%52.46%16.67%
Jazz Pharmaceuticals12.81%21.66%11.90%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Merck & Co., Inc. and Jazz Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Jazz Pharmaceuticals051302.72

Merck & Co., Inc. currently has a consensus price target of $94.1538, suggesting a potential upside of 18.31%. Jazz Pharmaceuticals has a consensus price target of $157.1765, suggesting a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Merck & Co., Inc..

Pfizer (NYSE:PFE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Insider & Institutional Ownership

70.3% of Pfizer shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Pfizer and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer31.17%25.76%9.91%
Jazz Pharmaceuticals12.81%21.66%11.90%

Analyst Ratings

This is a breakdown of current recommendations for Pfizer and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08402.33
Jazz Pharmaceuticals051302.72

Pfizer presently has a consensus price target of $38.6083, suggesting a potential upside of 11.88%. Jazz Pharmaceuticals has a consensus price target of $157.1765, suggesting a potential upside of 41.35%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Pfizer.

Risk and Volatility

Pfizer has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pfizer and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.70$16.27 billion$2.9511.70
Jazz Pharmaceuticals$2.16 billion2.85$523.37 million$14.607.62

Pfizer has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Jazz Pharmaceuticals beats Pfizer on 9 of the 14 factors compared between the two stocks.

Eli Lilly And Co (NYSE:LLY) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Earnings & Valuation

This table compares Eli Lilly And Co and Jazz Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly And Co$22.32 billion7.15$8.32 billion$6.0427.63
Jazz Pharmaceuticals$2.16 billion2.85$523.37 million$14.607.62

Eli Lilly And Co has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Eli Lilly And Co and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly And Co04712.75
Jazz Pharmaceuticals051302.72

Eli Lilly And Co presently has a consensus target price of $169.7273, indicating a potential upside of 1.70%. Jazz Pharmaceuticals has a consensus target price of $157.1765, indicating a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Eli Lilly And Co.

Profitability

This table compares Eli Lilly And Co and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly And Co23.97%194.18%15.11%
Jazz Pharmaceuticals12.81%21.66%11.90%

Institutional and Insider Ownership

77.4% of Eli Lilly And Co shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.1% of Eli Lilly And Co shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Eli Lilly And Co has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

Summary

Eli Lilly And Co beats Jazz Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jazz Pharmaceuticals and AbbVie, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals051302.72
AbbVie031402.82

Jazz Pharmaceuticals currently has a consensus target price of $157.1765, indicating a potential upside of 41.35%. AbbVie has a consensus target price of $106.80, indicating a potential upside of 7.87%. Given Jazz Pharmaceuticals' higher possible upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than AbbVie.

Profitability

This table compares Jazz Pharmaceuticals and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals12.81%21.66%11.90%
AbbVie24.77%-169.80%18.52%

Earnings and Valuation

This table compares Jazz Pharmaceuticals and AbbVie's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion2.85$523.37 million$14.607.62
AbbVie$33.27 billion4.40$7.88 billion$8.9411.07

AbbVie has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jazz Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Institutional & Insider Ownership

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 72.4% of AbbVie shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bristol-Myers Squibb (NYSE:BMY) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bristol-Myers Squibb and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031102.79
Jazz Pharmaceuticals051302.72

Bristol-Myers Squibb currently has a consensus price target of $68.1667, indicating a potential upside of 13.25%. Jazz Pharmaceuticals has a consensus price target of $157.1765, indicating a potential upside of 41.35%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Bristol-Myers Squibb.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.21$3.44 billion$4.6912.83
Jazz Pharmaceuticals$2.16 billion2.85$523.37 million$14.607.62

Bristol-Myers Squibb has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb3.08%30.06%10.96%
Jazz Pharmaceuticals12.81%21.66%11.90%

Institutional & Insider Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Bristol-Myers Squibb on 8 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.4$142.98+1.4%$377.31 billion$82.06 billion18.91Increase in Short Interest
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.3$79.58+1.0%$199.53 billion$46.84 billion20.15Decrease in Short Interest
Pfizer logo
PFE
Pfizer
2.7$34.51+0.0%$191.70 billion$51.75 billion12.33
Eli Lilly And Co logo
LLY
Eli Lilly And Co
2.1$166.89+1.8%$159.84 billion$22.32 billion27.59Decrease in Short Interest
AbbVie logo
ABBV
AbbVie
2.5$99.01+0.1%$146.02 billion$33.27 billion17.52
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.2$60.19+1.7%$133.82 billion$26.15 billion74.31
Zoetis logo
ZTS
Zoetis
1.9$138.60+0.7%$65.82 billion$6.26 billion41.37
Royalty Pharma logo
RPRX
Royalty Pharma
1.1$46.11+0.8%$27.23 billionN/A0.00
Horizon Therapeutics logo
HZNP
Horizon Therapeutics
1.9$58.11+4.9%$10.83 billion$1.30 billion20.53
Mylan logo
MYL
Mylan
1.6$15.93+1.1%$8.23 billion$11.50 billion132.76
Perrigo logo
PRGO
Perrigo
1.9$55.29+0.2%$7.52 billion$4.84 billion40.36
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$23.98+1.9%$4.19 billion$114.62 million-9.19
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.6$52.37+1.5%$2.21 billion$421.03 million-2,617.19Analyst Report
Heavy News Reporting
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.72+2.8%$1.91 billion$306.49 million19.00
Zogenix logo
ZGNX
Zogenix
2.0$29.19+0.4%$1.62 billion$3.65 million-3.09
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$23.58+0.1%$1.25 billion$392.76 million10.87
Omeros logo
OMER
Omeros
1.5$15.15+1.0%$836.18 million$111.81 million-8.76
Endo International logo
ENDP
Endo International
1.5$3.62+3.3%$801.69 million$2.91 billion-2.96
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.3$23.07+0.5%$758.50 million$15.96 million-6.73
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$4.49+0.9%$444.73 million$111.39 million-49.83
Lannett logo
LCI
Lannett
1.6$7.12+0.7%$287.09 million$655.41 million-8.68
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$5.25+1.9%$222.13 million$16.54 million-1.50
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.4$3.24+2.8%$49.19 million$47.53 million-10.80Decrease in Short Interest
VIVUS logo
VVUS
VIVUS
1.2$0.79+2.5%$14.11 million$69.76 million-0.29
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.